[{"orgOrder":0,"company":"PerkinElmer","sponsor":"Sirion Biotech","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PerkinElmer","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"PerkinElmer \/ PerkinElmer","highestDevelopmentStatusID":"4","companyTruncated":"PerkinElmer \/ PerkinElmer"}]

Find Clinical Drug Pipeline Developments & Deals by PerkinElmer

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration combines SIRION’s adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy and expertise in viral vector development and production with CRG’s deep knowledge of genetic regulatory mechanisms.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 16, 2022

                          Lead Product(s) : AAV-based Gene Therapy

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Recipient : Sirion Biotech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank